Most recent Article
Sativa Group welcomes new Food Standard Agency (“FSA”) guidelines (14 February 2020)
ativa Group notes the recent announcement by the Food Standards Agency (“FSA”) concerning the safe use of CBD products and the timetable for Novel Food authorisation. It welcomes the clarity of a regulatory framework as an important step leading to the development of a safe and legal market in the UK for CBD. Read more…

Latest articles

Sativa Group Plc – Trading update (10 February 2020)

The Company is pleased to provide a trading update for the year ended 31 December 2019, along with a general business update. 2019 was a year of significant progress for the Group. The strategic focus and reorganisation that has taken place since the arrival of Henry Buckley has enabled…

PRESS RELEASE: Placing and subscription to raise approximately £1.38 million

Sativa Group plc [NEX: SATI], the UK’s leading quoted CBD wellness and medicinal cannabis group, is pleased to announce that it has raised approximately £1.38 million (before expenses) by way of a placing and subscription of 34,500,000 new ordinary shares of 0.25 pence each (“New Ordinary Shares”) at a price of 4 pence per New Ordinary Share (the “Placing Price”) (the “Fundraising”).

PRESS RELEASE: Company Update (25th November 2019)

Following the appointment of Henry Lees-Buckley as Chief Executive Officer in August 2019, the Group has developed to become a UK-centric, cohesive and complementary group of five operating subsidiaries.

PRESS RELEASE: PDMR Shareholding (11th November 2019)

Sativa Group plc (NEX: SATI) has been notified that on 8 November 2019, George Thomas, MD of George Botanicals and a PDMR, completed the purchase of 500,000 ordinary shares of 0.25 pence each in the Company (“Ordinary Shares”) at an average price of 5.375p per share.

PRESS RELEASE: Home Office Grants Sativa a Controlled Drug Licence (16th October 2019)

Sativa Group Plc (NEX: SATI), the UK’s leading quoted CBD wellness and medicinal cannabis Group, is pleased to announce that its wholly owned subsidiary, Sativa Cultivation and Extraction Ltd, has been awarded a Controlled Drug licence for cannabis (with THC content of greater than 0.2%) cultivation, production, possession and supply, at its Somerset headquarters, by the UK Home Office.